ClinicalTrials.gg
CompletedNCT03995472Updated Sep 28, 2023

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

A Phase 1 interventional study of SHR-1501 and SHR-1316 in Advanced Malignancies, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and tolerability of SHR-1501 in combination with SHR-1316 in patients with advanced malignancies and to provide a recommended dose (RP2D) for subsequent clinical studies.

02

Conditions studied

  • Advanced Malignancies
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All Patients All patients must meet all the following criteria to be eligible to participate:
  1. Voluntarily participate in this clinical study, understand the research procedure and be able to sign in writing;
  2. Subjects must be willing and able to follow the research protocol;
  3. Aged 18-75 years old when the informed consent form is signed;
  4. Have a or cytologically confirmed diagnosis of advanced or tumor ;
  5. Patients' malignancies must be to standard treatment, or patients cannot tolerate standard treatment, or patients have actively refused standard therapy;
  6. FFPE tumor tissue or unstained slides of tumor sample must be obtained from patients enrolled in the dose expansion or indication expansion stage, both preserved samples collected within 6 months before the first dose (or up to 12 months prior to the first dose) and fresh samples (preferred) are acceptable;
  7. ECOG PS score of 0-1;
  8. Have a of ≥ 12 weeks;
  9. Adequate organ function defined according to the protocol, These results should be completed within 14 days prior to the first study treatment:
  10. Non-surgically sterilized women of childbearing age or male subjects are required to consent to the use of at least one medically approved (eg intrauterine devices, contraceptives or condoms) is performed during the study treatment period and within 3 months of the end of the study treatment period.

Exclusion criteria

Exclusion Criteria:

  1. Patients with cancerous meningitis (ie meningeal );
  2. Patients with active central nervous system (CNS) metastasis.
  3. Spinal cord compression that cannot be radically treated with surgery and/or radiotherapy cannot be enrolled.
  4. Patients with double cancer or more serious cancer;
  5. Patients with a history of diseases;
  6. Significant clinical significance in the history of cardiovascular disease;
  7. Arterial/venous thrombosis events such as cerebrovascular accidents deep vein thrombosis and pulmonary embolism within 6 months prior to first administration;
  8. Have a history of immunodeficiency including infection;
  9. Active or patients;
  10. Any disease or symptom that is not appropriate for inclusion in this study determined by the investigator.;
  11. Patients have undergone major surgery within 28 days prior to the first dose (except for diagnostics);
  12. Those who used a within 4 weeks prior to the first dose or expect a live attenuated vaccine during the study period;
  13. Those who received other clinical trials within 4 weeks prior to the first study;
  14. Those who received systemic therapy within 2 weeks prior to the first study dose;
  15. Patients who have previously received bone marrow transplantation or solid organ transplantation;
  16. A history of severe allergic reactions to other monoclonal antibody/fusion protein drugs;
  17. Mental illness, alcohol abuse, drug abuse or substance abuse;
  18. Any disease or condition that causes reasonable suspicion to prohibit the use of the study drug or affect the interpretation of the study results or the patient is at high risk of treatment complications (any other disease, metabolic disorder, physical examination results or laboratory tests abnormalities);
  19. Pregnant or lactating women or women planning to become pregnant during the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    SHR-1501 and SHR-1316 dose escalation

    SHR-1501 given subcutaneously with different doses. SHR-1316 given intravenously.

    Drug: SHR-1501 · Drug: SHR-1316

  • Experimental
    SHR-1501 and SHR-1316 dose expansion

    SHR-1501 given subcutaneously with different doses. SHR-1316 given intravenously.

    Drug: SHR-1501 · Drug: SHR-1316

  • Experimental
    SHR-1501 and SHR-1316 Indication expansion

    SHR-1501 given subcutaneously with a recommended dose. SHR-1316 given intravenously.

    Drug: SHR-1501 · Drug: SHR-1316

Interventions

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity and Maximum tolerated dose

    Dose-limiting toxicity and Maximum tolerated dose in patients with advanced tumors treated by SHR-1501 combined with SHR-1316.

    Time frame: Approximately 42 Days.

  2. Recommended Phase 2 dose (RP2D)

    Recommended Phase 2 dose (RP2D) based on comprehensive evaluation

    Time frame: Approximately 2 years

  3. Adverse event/Serious adverse event

    Incidence/severity of adverse events/serious adverse events (rated based on CTC AE v5.0)

    Time frame: Approximately 2 years

Secondary outcomes

  1. Pharmacokinetic (PK)

    Single dose: maximum concentration (Cmax)

    Time frame: Approximately 2 years

  2. Pharmacokinetic (PK)

    Single dose: time to maximum concentration (Tmax)

    Time frame: Approximately 2 years

  3. Pharmacokinetic (PK)

    Single dose: areas under the concentration-time curve (AUClast and AUCinf)

    Time frame: Approximately 2 years

  4. Pharmacokinetic (PK)

    Single dose: half-life (t1/2)

    Time frame: Approximately 2 years

  5. Pharmacokinetic (PK)

    Single dose: clearance (CL)

    Time frame: Approximately 2 years

  6. Pharmacokinetic (PK)

    Single dose: mean residence time (MRT)

    Time frame: Approximately 2 years

  7. Pharmacokinetic (PK)

    Single dose: volume at steady state (Vss)

    Time frame: Approximately 2 years

  8. Pharmacokinetic (PK)

    Multiple doses (at steady state, if applicable): maximum concentration at steady state (Css_max)

    Time frame: Approximately 2 years

  9. Pharmacokinetic (PK)

    Multiple doses (at steady state, if applicable): time to maximum concentration (Tss_max)

    Time frame: Approximately 2 years

  10. Pharmacokinetic (PK)

    Multiple doses (at steady state, if applicable): area under the concentration-time curve at steady state (AUCss)

    Time frame: Approximately 2 years

  11. Pharmacokinetic (PK)

    Multiple doses (at steady state, if applicable): t1/2

    Time frame: Approximately 2 years

  12. Pharmacokinetic (PK)

    Multiple doses (at steady state, if applicable):steady-state minimum concentration at steady state (Css_min)

    Time frame: Approximately 2 years

  13. Pharmacokinetic (PK)

    Multiple doses (at steady state, if applicable): average concentration at steady state(Css_av)

    Time frame: Approximately 2 years

  14. Pharmacokinetic (PK)

    Multiple doses (at steady state, if applicable): accumulation ratio (Rac)

    Time frame: Approximately 2 years

  15. Immune related features

    indicated by the count of CD8+ T-lymphocytes in peripheral blood at scheduled post-dose time points.

    Time frame: Approximately 2 years

  16. Immune related features

    indicated by the percentage of CD8+ T-lymphocytes in peripheral blood at scheduled post-dose time points.

    Time frame: Approximately 2 years

  17. Immune related features

    indicated by the count of natural killer (NK) cells in peripheral blood at scheduled post-dose time points.

    Time frame: Approximately 2 years

  18. Immune related features

    indicated by the percentage of natural killer (NK) cells in peripheral blood at scheduled post-dose time points.

    Time frame: Approximately 2 years

  19. Objective response rate

    Percentage of participants with CR or PR.

    Time frame: Approximately 2 years

  20. Disease control rate

    Percentage of participants with CR or PR or SD.

    Time frame: Approximately 2 years

  21. Duration of response

    Duration of time of tumor remission.

    Time frame: Approximately 2 years

  22. progression-free survival

    Progression-free survival time.

    Time frame: Approximately 2 years

  23. 12 months overall survival

    12-month survival rate.

    Time frame: Approximately 2 years

  24. Durable clinical benefit rate at 6 month

    Percentage of participants with CR or PR or SD lasts over six months.

    Time frame: Approximately 2 years

  25. Immunogenicity

    The immunogenicity of SHR-1501 single drug and the immunogenicity of SHR-1316 combined with SHR-1501. The indicator includes number of participants with anti-drug antibody positive or neutralizing antibody positive.

    Time frame: Approximately 2 years

07

Study locations

5 sites
  • Sydney Southwest Private Hospital
    Liverpool, New South Wales 2170, Australia
  • Scientia Clinical Research
    Randwick, New South Wales 2031, Australia
  • Icon Cancer Centre South Brisbane
    South Brisbane, Queensland 4101, Australia
  • John Flynn Private Hospital
    Tugun, Queensland 4224, Australia
  • Guangdong General Hospital & Guangdong Academy of Medical Sciences
    Guangzhou, Guangdong 510080, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Jan 2023, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2019
First posted
Jun 24, 2019
StartActual
Feb 14, 2020
Primary completionActual
Jan 12, 2023
CompletionActual
Jan 12, 2023
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03995472
Responsible party
Sponsor
First posted
Jun 24, 2019
Start date
Feb 14, 2020
Primary completion
Jan 12, 2023
Completion
Jan 12, 2023
Last update
Sep 28, 2023

Study contacts

Yilong Wu, MD
study director · Guangdong General Hospital & Guangdong Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Efserakefusp alfa · Adebrelimab

Start the discussion